Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.
SynAct Pharma has received useful external validation for lead asset resomelagon’s dengue programme, with a World Health Organization (WHO)-led review published in The Lancet Microbe identifying it as one of only six candidates with sufficient efficacy...
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
SynAct Pharma has reported further analysis of the Phase IIb ADVANCE study (testing resomelagon in rheumatoid arthritis), providing a clearer explanation for the unexpectedly strong placebo response. Management estimates that around 20% of patients entered...
SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and commercial opportunity. Following June’s Phase IIb ADVANCE data, we expect RA to remain the principal value driver, with ACR20, CRP and SDAI signals ...
SynAct Pharma reported Q226 operating expenses of SEK24.6m, down 19% y-o-y, while the net loss narrowed to SEK22.0m and quarter-end cash stood at SEK14.2m. Post-period, the company secured a new financing facility of up to SEK100m from Fenja Capital,...
SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor for the co-development and commercialisation of resomelagon for dengue and other viral infections in Brazil. We view this agreement positively, as it builds...